Gapping down
In reaction to disappointing earnings/guidance:
- PETS -9.2%, CADE -8.2%, CALM -5.8%, SOI -1.1%, LII -0.9%
Other news:
- NTEC -78.9% (announces top-line data from Phase 3 trial of Accordion Pill-Carbidopa/Levodopa compared with immediate release CD/LD as a treatment for the symptoms of advanced Parkinson's disease -- ACCORDANCE study did not achieve statistical superiority)
- PAYS -6.5% (files for $150 mln mixed securities shelf offering)
- MRKR -4.6% (reports interim results of its MultiTAA T Cell Therapy)
- BHVN -4% (receives Complete Response Letter from the FDA for the 505(b)2 application seeking approval for NURTEC)
- CASI -3.2% (entered into $30 mln common stock Open Market Sale Agreementf)
- VNDA -1.8% (FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time related to new drug application for Hetlioz)
- TELL -1.5% (files for 45,999,999 share common stock offering by holders)
- ACRE -1% (files for $1.25 bln mixed securities shelf offering)
- NFLX -0.8% (Cautious view in Barrons) .
Analyst comments:
- MCFT -3.7% (downgraded to Mkt Perform from Strong Buy at Raymond James)
- MBUU -2.8% (downgraded to Mkt Perform from Strong Buy at Raymond James)
- KEYS -2.2% (downgraded to Neutral from Buy at Goldman)
- BC -1.8% (downgraded to Neutral from Overweight at JP Morgan)
- WLK -1.7% (downgraded to Reduce from Neutral at Nomura)
- MRVL -1.6% (downgraded to Neutral from Buy at Goldman)
- LYB -1.4% (downgraded to Neutral from Buy at Nomura)
- NDAQ -1.4% (downgraded to Sell from Neutral at Citigroup)